Covidien Unit Targets Watson Over Generic Exalgo

Law360, New York (December 15, 2010, 3:43 PM EST) -- A Covidien PLC subsidiary has sued specialty pharmaceutical company Watson Pharmaceuticals Inc. in an effort to stop it from marketing a generic version of painkiller Exalgo.

Missouri-based Mallinckrodt Inc. filed the patent infringement suit in the U.S. District Court for the District of New Jersey on Friday in response to Watson’s submission of an abbreviated new drug application seeking to gain U.S. Food and Drug Administration approval of hydromorphone hydrochloride extended-release tablets in 8 mg, 12 mg and 16 mg strengths before the patent-in-suit expires....
To view the full article, register now.